Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.

2.50
Hdl Handle:
http://hdl.handle.net/11287/620798
Title:
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.
Authors:
Corrie, P G [et al]; Goodman, Andrew
Abstract:
Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor (VEGF) shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of recurrence.
Citation:
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. 2018 Ann. Oncol.
Publisher:
Oxford Journals
Journal:
Annals of oncology : official journal of the European Society for Medical Oncology
Issue Date:
13-Jul-2018
URI:
http://hdl.handle.net/11287/620798
DOI:
10.1093/annonc/mdy229
PubMed ID:
30010756
Additional Links:
https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdy229
Type:
Journal Article
Language:
en
ISSN:
1569-8041
Appears in Collections:
Oncology; 2018 RD&E publications

Full metadata record

DC FieldValue Language
dc.contributor.authorCorrie, P G [et al]en
dc.contributor.authorGoodman, Andrewen
dc.date.accessioned2018-07-25T11:35:51Z-
dc.date.available2018-07-25T11:35:51Z-
dc.date.issued2018-07-13-
dc.identifier.citationAdjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. 2018 Ann. Oncol.en
dc.identifier.issn1569-8041-
dc.identifier.pmid30010756-
dc.identifier.doi10.1093/annonc/mdy229-
dc.identifier.urihttp://hdl.handle.net/11287/620798-
dc.description.abstractBevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor (VEGF) shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of recurrence.en
dc.language.isoenen
dc.publisherOxford Journalsen
dc.relation.urlhttps://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdy229en
dc.rightsArchived with thanks to Annals of oncology : official journal of the European Society for Medical Oncologyen
dc.subjectWessex Classification Subject Headings::Oncology. Pathology.en
dc.titleAdjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.en
dc.typeJournal Articleen
dc.identifier.journalAnnals of oncology : official journal of the European Society for Medical Oncologyen
dc.type.versionIn press (epub ahead of print)en

Related articles on PubMed

All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.